Key Insights from AACR: Chinese Biotech, Oncology Communication Gaps, and Breakthroughs in RAS Inhibitors

Final Edition: AACR in 30 Seconds Recap

This is the last edition of STAT’s popup newsletter, AACR in 30 seconds, your concise guide to the American Association for Cancer Research’s annual meeting. If you’re not already a STAT+ subscriber, consider subscribing—there’s currently a 60% off promotion on annual subscriptions.

Revolution Medicines Unveils Next-Gen RAS Inhibitor at AACR

Revolution Medicines’ sessions at AACR drew significant attention, with attendees focusing on the company’s latest advancements. While media coverage centered on daraxonrasib data for frontline pancreatic cancer, Revolution Medicines also disclosed promising activity in a new compound, RM-055.

Mark Goldsmith, CEO of Revolution Medicines, described RM-055 as part of a new class of “catalytic inhibitors.” Unlike traditional inhibitors, RM-055 can remove a phosphate from GTP-RAS—the active form of RAS—effectively turning the protein off. This mechanism addresses a critical challenge in cancer treatment: resistance to RAS inhibitors.

How RM-055 Targets RAS Addiction in Cancer

Cancer often develops resistance to RAS inhibitors by amplifying mutant RAS, flooding cells with the oncoprotein and overwhelming the inhibitor. RM-055’s catalytic ability to deactivate multiple mutant RAS proteins may represent the next step in combating RAS-addicted cancers.

For the full story, continue to STAT+.

AACR Highlights: Chinese Biotech and Oncology’s Communication Gap

The AACR meeting also spotlighted discussions around Chinese biotech and broader challenges in oncology communications. These topics underscored the need for clearer dialogue between researchers, clinicians, and the public to accelerate progress in cancer treatment.